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Background/Aims: Osteoprotegerin (OPG) and fetuin-A are vascular calcification 
regulators that may be related to high cardiovascular (CV) mortality in hemodi-
alysis (HD) patients. We evaluated the relationship between OPG, fetuin-A, and 
pulse wave velocity (PWV), a marker of vascular stiffness, and determined wheth-
er OPG and fetuin-A were independent predictors of CV events in HD patients.
Methods: We conducted a prospective observational study in 97 HD patients. 
OPG and fetuin-A were measured at baseline and arterial stiffness was evaluated 
by PWV. All patients were stratified into tertiles according to serum OPG levels. 
Results: A significant trend was observed across increasing serum OPG con-
centration tertiles for age, HD duration, systolic blood pressure, cholesterol, 
triglycerides, and PWV. Multiple linear regression analysis revealed that diabe-
tes (β = 0.430, p = 0.000) and OPG levels (β = 0.308, p = 0.003) were independently 
associated with PWV. The frequency of new CV events was significantly higher 
in the upper OPG tertiles compared with those in the lower OPG tertiles. In Cox 
proportional hazards analysis, upper tertiles of OPG levels were significantly as-
sociated with CV events (hazard ratio = 4.536, p = 0.011). 
Conclusions: Serum OPG, but not fetuin-A, levels were closely associated with in-
creased vascular stiffness, and higher OPG levels may be independent predictors 
of new CV events in HD patients.
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INTRODUCTION
Cardiovascular (CV) disease is a major cause of death 
in uremic patients. Earlier studies have reported that 
vascular calcification is associated with increased arte-
rial stiffness and may contribute to high CV mortality 
in end-stage renal disease (ESRD) patients [1,2]. Aortic 
pulse wave velocity (PWV), which is an index of arteri-
al distensibility, is the gold standard measure of arte-
rial stiffness [3].
Osteoprotegerin (OPG), a soluble decoy receptor of 
the osteoclast activator, acts as an important regulato-
ry molecule in vascular calcification, independent of 
classical risk factors [4,5]. Fetuin-A (a2-Heremans-
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Schmidt glycoprotein) is a systemic inhibitor of ecto-
pic mineral deposition, particularly in chronic kidney 
disease (CKD) patients, who suffer from progressive 
arterial calcification [6]. Serum OPG and fetuin-A lev-
els have been associated with the stiffening of large 
vessel walls, which may contribute to the high CV 
mortality observed in hemodialysis (HD) patients [7-9]. 
However, conflicting data on their impact on vascular 
measures and CV mortality in maintenance HD pa-
tients remains to be resolved [10-13].
In this study, we evaluated the link between OPG, 
fetuin-A and vascular stif fness, and determined 
whether OPG and fetuin-A levels were associated with 
the onset of new CV events and all-cause mortality in 
HD patients.
METHODS
Patients
Ninety-seven patients on chronic HD (54 males, 43 fe-
males; mean age, 56.5 ± 12.2 years; range, 28 to 77 years) 
from the two dialysis units of the University Depart-
ment of Nephrology at Gangnam Severance Hospital, 
Seoul, Korea and CHA Bundang Medical Center, CHA 
University, Seongnam, Korea were enrolled in this 
prospective observational study between January and 
March 2008. All participants had been on HD > 3 
months (mean dialysis duration, 46 months; range, 6 
to 227) and were clinically stable. This study was ap-
proved by the Institutional Review Board for human 
research at Yonsei University College of Medicine, 
Seoul, Korea, and all participants provided their writ-
ten informed consent prior to study entry. Patients 
were followed for a median of 40 months (range, 14 to 
42). Medical records were reviewed for clinical history 
and prior CV events. Primary endpoints were newly 
developed CV events defined as ischemic heart dis-
ease, heart failure, cerebrovascular disease, peripheral 
vascular disease, and sudden death. Ischemic heart 
disease (angina pectoris or myocardial infarction) was 
diagnosed by any of the following: typical angina 
symptoms, ischemic changes in electrocardiogram or 
echocardiogram, or coronary artery stenosis con-
firmed by catheterization. Heart failure was defined 
by typical symptoms, such as dyspnea, shortness of 
breath, or raised jugular venous pressure with systolic 
or diastolic dysfunction by echocardiography in accor-
dance with the guidelines of the European Society of 
Cardiology [14]. Cerebrovascular disease (transient 
ischemic attack, cerebral infarction, or cerebral hem-
orrhage) was confirmed both by typical symptoms 
with physical findings and by computed tomography 
(CT) or magnetic resonance imaging. Peripheral vas-
cular disease was diagnosed when the patient had typ-
ical symptoms, abnormal ankle brachial pressure in-
dex, positive CT or CT angiography f indings, or 
peripheral artery stenosis confirmed by catheteriza-
tion.
Biochemical measurements
Baseline biochemical parameters, including fasting 
glucose, lipid profiles, calcium, phosphate, and intact 
parathyroid hormone (iPTH), were collected prior to 
midweek dialysis at the time of arterial stiffness mea-
surements. Serum OPG and fetuin-A levels were mea-
sured by ELISA using a commercially available kit 
(R&D Systems, Minneapolis, MN, USA). 
Assessment of arterial stiffness
Heart-femoral PWV, which represents aortic stiffness 
by measuring the time delay between the rapid up-
stroke of the feet of simultaneously recorded pulse 
waves in the heart and the femoral arteries [15], was 
calculated with a VP-2000 pulse wave unit (Nippon 
Colin Ltd., Komaki, Japan). After a 5-minute rest peri-
od, the PWV was measured in a supine position. Ca-
rotid and femoral artery pressure waveforms were re-
corded in multielement tonometry sensors at the left 
carotid and the left femoral arteries. The electrocar-
diogram was monitored by electrodes on both wrists. 
The heart sounds S1 and S2 were detected by a micro-
phone on the left edge of the sternum at the third in-
tercostal space. The waveform analyzer measured the 
time intervals between S2 and the notch of the carotid 
pulse wave (Thc), and again between the carotid and 
femoral artery pulse waves (Tcf ). The sum of Thc and 
Tcf gave the time required for pulse waves to travel 
from the heart (aortic orif ice) to the femoral artery 
(Thf ). The hf PWV was calculated from the equation 
Lhf / (Thc + Tcf ), where Lhf is the distance from the 
heart to the femoral artery [16].
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Statistical analysis
All values are expressed as means ± SD. Pearson cor-
relation analysis was performed to estimate the cor-
relations between OPG, fetuin-A, and other variables. 
One-way analysis of variance was used to compare 
each baseline variable among OPG tertile groups. 
Multiple linear regression analysis was used to evalu-
ate independent predictors of vascular stiffness. Sur-
vival was evaluated by Kaplan-Meier curves, and com-
pared using the log-rank test . To estimate the 
relationship of OPG levels on CV events and all-cause 
mortality, Cox proportional hazard regression analy-
ses were used. Hazard ratios (HR) are presented with 
their 95% confidence intervals (CIs) in parentheses. 
Values of p < 0.05 were considered to indicate statisti-
cal significance. Statistical analysis was performed us-
ing SPSS version 19.0 for Windows (IBM Co., Armonk, 
NY, USA).
RESULTS
Baseline characteristics and biochemical data
Fifty-six percent of the study subjects were males. 
Their ages ranged from 28 to 77 years (mean age, 56.5 ± 
12.2). Sixty percent of the patients were diabetic. The 
causes of ESRD were diabetes (n = 44), hypertension (n 
= 34), glomerulonephritis (n = 12), polycystic kidney 
disease (n = 2), and other/unknown (n = 5). The mean 
OPG concentration was 2,407.0 ± 1,072.5 pg/mL (range, 
232 to 5,155). The mean fetuin-A level was 152.4 ± 155.9 
mg/mL (range, 7 to 1,372). Twenty patients (20.6%) were 
smokers. Eighty-two patients (84.5%) received angio-
tensin-converting enzyme inhibitors or angiotensin-II 
receptor blockers. Forty-four patients (45.3%) received 
statin treatment and 33 patients (34.0%) took calci-
um-based phosphate-binding agents and/or activated 
vitamin D3. Twenty-four patients (24.7%) had a history 
of CV disease.
Patients were stratified into tertiles according to se-
rum OPG levels (lower tertile ≤ 1,907 pg/mL; middle 
tertile 1,908 to 2,737 pg/mL; upper tertile ≥ 2,738 pg/
mL). A signif icant trend of increasing serum OPG 
concentrations was observed across the tertiles for age 
(p = 0.000), HD duration (p = 0.009), systolic blood 
pressure (p = 0.007), cholesterol (p = 0.011), triglycerides 
(p = 0.012), and PWV (p = 0.034). No significant differ-
ences were observed in any other variables across the 
serum OPG level tertiles (Table 1).
Serum OPG levels showed a linear increase with age 
(r = 0.486, p = 0.000), HD duration (r = 0.212, p = 0.038), 
and C-reactive protein (CRP) (r = 0.212, p = 0.040). 
Moreover, increasing OPG levels were associated with 
increased PWV (r = 0.291, p = 0.004). Fetuin-A showed 
no correlations with variables other than total choles-
terol (r = 0.227, p = 0.025) and low density lipid choles-
terol (LDL-C) (r = 0.223, p = 0.028) (Table 2).
Independent predictors of PWV
In univariate analysis, PWV was positively associated 
with age (β = 0.319, p = 0.001), diabetes (β = 0.391, p = 
0.000), hypertension (β = 0.270, p = 0.007), and OPG 
levels (β = 0.291, p = 0.004) and negatively associated 
with hemoglobin levels (β = -0.207, p = 0.042). Among 
these variables, only diabetes and OPG levels were in-
dependently associated with PWV (β = 0.430, p = 0.000; 
β = 0.308, p = 0.003, respectively) in a multivariate lin-
ear regression model (Table 3).
Association between OPG, fetuin-A levels, and CV 
events
During the 3.5-year follow-up period, 34 patients had 
45 new CV events, which included ischemic heart dis-
ease (n = 16), heart failure (n = 14), cerebrovascular dis-
ease (n = 11), peripheral vascular disease (n = 3), and 
sudden death (n = 1). Of these 34 patients, seven experi-
enced more than one CV event. During the study peri-
od, 18 patients (18.6%) died. Eleven (61.1%) of them 
were due to CV causes; coronary heart disease (n = 6, 
54.5%), heart failure (n = 3, 27.3%), cerebrovascular 
hemorrhage (n = 1, 9.1%), and sudden cardiac death (n 
= 1, 9.1%). Non-CV deaths (38.9%) consisted of septic 
shock (n = 4, 57.1%), gastrointestinal bleeding (n = 1, 
14.3%), and malignancy (n = 2, 28.6%). 
Kaplan-Meier analysis showed that CV events and 
all-cause mortality were significantly more frequent 
in the upper OPG tertiles compared with the lower 
OPG tertiles (p = 0.003 and p = 0.030, respectively, log-
rank test) (Fig. 1). In univariate Cox proportional haz-
ard models, the following variables were related to CV 
events: age (HR = 1.452, p = 0.008), the presence of dia-
betes (HR = 1.590, p = 0.003), CRP (HR = 1.071, p = 0.003), 
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upper OPG tertiles (HR = 4.342, p = 0.004), and PWV 
(HR = 1.001, p = 0.047). By contrast, gender, smoking, 
body mass index, blood pressure, lipid profile, and 
bone mineral markers were not significantly associat-
ed with CV events. In multivariate analysis, only upper 
tertiles of serum OPG remained a significant predic-
tor of new onset CV events (HR = 4.536, p = 0.011) (Table 
4). In univariate analysis for all-cause mortality, asso-
ciated factors were age (HR = 1.300, p = 0.015), the pres-
ence of diabetes (HR = 1.230, p = 0.035), increased PWV 
(HR = 1.001, p = 0.045), and upper OPG tertiles (HR = 
1.550, p = 0.033). In the multivariate Cox hazard models, 
age was a significant predictor of all-cause death (HR 
= 1.132, p = 0.010) (Table 5). Furthermore, Kaplan-Meier 
analysis and Cox proportional hazard models indicat-
ed no difference in the frequencies of CV events and 
all-cause mortality according to fetuin-A level (data 
not shown).
DISCUSSION
The results of this study indicate that serum OPG lev-
els were associated with arterial stiffness represented 
by PWV, and that higher OPG levels predict the onset 
of new CV events in HD patients. In contrast, fetuin-A 
Table 1. Comparison of biochemical and demographic data according to tertile of osteoprotegerin
Lower OPG (n = 32) Middle OPG (n = 33) Upper OPG (n = 32) p value
Age, yr 47.4 ± 13.3 59.7 ± 9.5 61.3 ± 8.9 0.000a
Male sex, % 46.8 66.6 59.3 0.277
BMI, kg/m2 22.6 ± 3.3 21.9 ± 3.3 21.9 ± 3.3 0.672
HD duration, mon 38.1 ± 31.0 61.7 ± 44.8 73.9 ± 55.3 0.009a
DM 19 (59) 24 (73) 16 (50) 0.234
SBP, mmHg 137.4 ± 19.8 153.5 ± 23.9 140.6 ± 19.2 0.007a
DBP, mmHg 74.5 ± 13.7 77.0 ± 14.5 73.4 ± 12.9 0.566
Ca, mg/dL 8.9 ± 0.6 9.0 ± 0.7 9.3 ± 0.9 0.219
P, mg/dL 4.9 ± 1.3 5.0 ± 1.4 4.9 ± 2.2 0.974
iPTH, pg/mL 291.9 ± 269.4 169.7 ± 246.4 200.0 ± 214.1 0.142
Albumin, g/dL 3.9 ± 0.3 3.8 ± 0.4 3.8 ± 0.3 0.508
CRP, mg/dL 0.8 ± 1.7 0.6 ± 1.2 2.9 ± 6.9 0.029a
Hemoglobin, g/dL 10.6 ± 0.8 10.2 ± 0.9 10.4 ± 1.2 0.286
Cholesterol, mg/dL 148.2 ± 40.9 124.8 ± 24.2 132.1 ± 26.4 0.011a
Triglyceride, mg/dL 138.6 ± 83.4 94.5 ± 53.2 97.3 ± 48.9 0.012a
HDL-C, mg/dL 36.6 ± 10.9 37.5 ± 8.8 40.6 ± 14.5 0.386
LDL-C, mg/dL 86.0 ± 39.2 70.5 ± 21.8 73.6 ± 28.3 0.107
Fetuin-A, mg/mL 206.1 ± 250.3 115.7 ± 50.3 131.3 ± 100.6 0.051
PWV, cm/sec 1,136.7 ± 340.0 1,254.0 ± 271.2 1,352.6 ± 358.0 0.034a
History of CVD 4 (12.5) 8 (24.2) 12 (37.5) 0.010a
New onset CV events 5 (15.6) 11 (33.3) 18 (56.3) 0.005a
Values are presented as mean ± SD or number (%). Serum OPG levels were classif ied into three groups: ≤ 1,907 pg/mL 
(lower OPG), 1,908 to 2,737 pg/mL (middle OPG), ≥ 2,738 pg/mL (upper OPG). Analysis of variance between OPG tertiles was 
performed. 
OPG, osteoprotegerin; BMI, body mass index; HD, hemodialysis; DM, diabetes mellitus; SBP, systolic blood pressure; DBP, 
diastolic blood pressure; iPTH, intact parathyroid hormone; CRP, C-reactive protein; HDL-C, high density lipid cholesterol; 
LDL-C, low density lipid cholesterol; PWV, pulse wave velocity; CVD, cardiovascular disease; CV, cardiovascular.
ap < 0.05. 
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Table 2. Association between osteoprotegerin, fetuin-A, and biochemical parameters
Parameter
OPG Fetuin-A
p value r p value r
Age 0.000 0.486 0.088 -
Sex, male: female 0.546 - 0.135 -
Hemodialysis duration 0.038 0.212 0.662 -
Diabetes mellitus 0.691 - 0.646 -
Body mass index 0.620 - 0.253 -
Current smoking 0.676 - 0.427 -
Systolic blood pressure 0.488 - 0.245 -
Diastolic blood pressure 0.323 - 0.365 -
Calcium 0.182 - 0.732 -
Phosphate 0.758 - 0.688 -
iPTH 0.296 - 0.080 -
CRP 0.040 0.212 0.491 -
Albumin 0.147 - 0.510 -
Hemoglobin 0.199 - 0.161 -
Total cholesterol 0.518 - 0.025 0.227
HDL-C 0.452 - 0.694 -
LDL-C 0.945 - 0.028 0.223
Triglyceride 0.018 -0.236 0.167 -
OPG - - 0.139 -
Fetuin A 0.139 - - -
PWV 0.004 0.291 0.905 -
All associations were tested by means of Pearson correlation analyses. 
OPG, osteoprotegerin; iPTH, intact parathyroid hormone; CRP, C-reactive protein; HDL-C, high density lipid cholesterol; 
LDL-C, low density lipid cholesterol; PWV, pulse wave velocity.
Table 3. Multiple linear regression analysis of risk factors associated with pulse wave velocity
Univariate models Multivariate models
β p value β p value
Age, per yr 0.319 0.001a 0.023 0.832
DM 0.391 0.000a 0.430 0.000a
Hypertension 0.270 0.007a 0.161 0.075
Hemoglobin -0.207 0.042a -0.109 0.233
OPG, per pg/mL 0.291 0.004a 0.308 0.003a
Fetuin-A 0.012 0.905 -    -
CRP 0.073 0.479 - -
DM, diabetes mellitus; OPG, osteoprotegerin; CRP, C-reactive protein.
ap < 0.05. 
673
Lee JE, et al. OPG and CV events in HD patients
www.kjim.orghttp://dx.doi.org/10.3904/kjim.2013.28.6.668
showed no associations with PWV or CV events in 
these HD patients.
Recent studies indicate that OPG is associated with 
PWV in CKD patients [9,10]. However, the data regard-
ing associations of fetuin-A with PWV or CV mortality 
in these patients are conflicting [8,11,17]. Hermans et 
al. [11] found no association between circulating fetu-
in-A and PWV and suggested that fetuin-A was not an 
independent predictor of aortic stiffness measured by 
PWV [17]. Here, we assessed serum fetuin-A simulta-
neously with serum OPG and PWV in HD patients. 
Several clinical factors such as age, high blood pres-
sure, inflammation, and diabetic status are known to 
influence vascular stiffness in CKD patients. After ad-
justment for these factors in this study, only OPG and 
diabetic status were significantly associated with PWV. 
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Figure 1. Kaplan-Meier analysis of cardiovascular (A) event survival and (B) all-cause mortality in tertiles of serum 
osteoprotegerin levels.
Table 4. Cox proportional hazard model for analysis of the risk factors associated with new-onset cardiovascular events
Cardiovascular events
HR 95% CI p value
Age 1.035 0.946–1.017 0.286
DM 1.902 0.766–4.723 0.165
CRP 1.034 0.985–1.086 0.180
PWV 1.001 1.000–1.002 0.210
OPG tertiles (vs. lower)
Middle 2.000 0.643–6.223 0.231
Upper 4.536 1.412–14.574   0.011a
HR, hazard ratio; CI, confidence interval; DM, diabetes mellitus; CRP, C-reactive protein; PWV, pulse wave velocity; OPG, 
osteoprotegerin.
ap < 0.05. 
A B
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These f indings support the hypothesis that OPG is 
significantly associated with arterial stiffness in HD 
patients. Furthermore, elevated OPG levels were asso-
ciated with vascular calcif ication in HD patients 
[18,19], and vascular calcification of the large arteries 
was associated with increased risk of CV mortality in 
these dialysis patients [20]. Sigrist et al. [8] suggested 
that elevated OPG was associated with a negative out-
come in stages four and five CKD patients. Nakashima 
et al. [9] also showed that OPG was associated with CV 
mortality, as well as arterial stiffness in normalbu-
minemic Japanese HD patients. Moreover, high serum 
OPG was reported to be an independent predictor of 
CV events in new HD patients [7]. The present study 
corroborates these earlier findings that significantly 
associate higher OPG with the onset of new CV events 
in dialysis patients. This supports the use of serum 
OPG levels as a predictive marker of vascular stiffness 
and risk of CV events in HD patients. However, our 
study failed to show an association between OPG lev-
els and all-cause mortality. This discrepancy may be 
due to the small sample size of the study, as well as the 
patients’ characteristics, which consisted of younger 
and more stable patients than in previous studies. For-
ty-two percent of the patients in our study experienced 
onset of new CV events; 18% of these patients died 
within 40 months. In contrast, Nishiura et al. [7] and 
Nakashima et al. [9] recorded 21% and 26% total 
deaths, respectively. Thus, the low death rate reported 
here may have skewed the all-cause morality results, 
which may differ upon further investigation using a 
larger sample size with a longer follow-up period.
Fetuin-A is a circulating glycoprotein synthesized in 
human liver tissue. As a negative acute phase protein 
in vivo [21], the serum concentration of fetuin-A de-
creases during both acute and chronic inflammation, 
such as in dialysis patients [22]. In addition, fetuin-A 
inhibits systemic calcification, and low circulating fe-
tuin-A levels are associated with high serum phos-
phate levels in the general population [23,24]. A recent 
study reported that the fetuin-A level is associated 
with PWV and calcification [17]. However, Hermans et 
al. [11] reported that after adjusting for age, gender, 
mean arterial pressure, and diabetic status, there was 
no significant relationship between fetuin-A and PWV 
in dialysis patients. Other reports have failed to cor-
relate fetuin-A and PWV in stage four and five CKD 
patients [8], similar to the results of this study. The 
data associating fetuin-A and mortality are also con-
tradictory. Low serum fetuin-A levels were significant-
ly associated with all-cause and CV mortality in ESRD 
patients [25,26] but not with all-cause mortality and 
CV mortality in nondiabetic CKD patients [12]. Our 
results also suggest that fetuin-A was not associated 
with CV mortality among dialysis patients. Therefore, 
fetuin-A is not predictive of arterial stiffness and CV 
mortality in HD patients.
Interestingly, we found that fetuin-A was associated 
with total cholesterol and LDL-C levels. This finding 
is consistent with a previous report of positive associa-
tions of fetuin-A with LDL-C and nonhigh density 
lipid cholesterol in nondiabetic HD patients [27]. This 
association may be due to an inhibitory effect of fetu-
in-A on adipose tissue, which leads to lipolysis and 
free fatty acid efflux and suggests that fetuin-A could 
be a good predictive marker of visceral adiposity in 
HD patients.
We found no evidence correlating serum OPG levels 
and mineral metabolism factors, such as calcium, 
phosphate, and iPTH, as reported previously [28]. 
These f indings suggest that circulating OPG levels 
might not be indicative of active bone resorption. Fur-
thermore, mineral metabolism factors were not asso-
ciated with PWV in our study. Previous reports showed 
a signif icant association between these two factors 
[20,29], while another study failed to demonstrate an 
Table 5. Cox proportional hazard model for analysis of the 
risk factors associated with all-cause mortality
All-cause mortality
HR 95% CI p value
Age 1.132 0.975–1.092   0.010a
DM 1.695 0.169–2.852 0.104
PWV 1.001 1.000–1.003 0.272
OPG tertiles (vs. lower)
Middle 1.152 1.018-1.317 0.087
Upper 1.580 1.205-1.643 0.306
HR, hazard ratio; CI, conf idence interval; DM, diabetes 
mellitus; PWV, pulse wave velocity; OPG, osteoprotegerin.
ap < 0.05. 
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association [30]. Considering the cross-sectional de-
sign of this study, a causal relationship cannot be de-
termined based on one-time measurement of these 
parameters. Thus, future repeated measurements are 
warranted to clarify the relationship between OPG 
levels and mineral metabolism.
There are reports suggesting a strong association 
between OPG and CRP [31,32]. Morena et al. [33] re-
ported that high OPG levels were a vascular risk factor 
only in dialysis patients who have high CRP levels. 
Those findings suggested that OPG might be predic-
tive of poor outcomes only in the presence of inflam-
mation. In our study, OPG and CRP were directly correlat-
ed in a univariate analysis. However, af ter adjustment, 
OPG levels were not significantly associated with CRP 
levels. Accordingly, we cautiously suggest that OPG is 
not a general marker of inflammation.
Our study has several limitations. First, the sample 
size was relatively small and few patients developed 
CV mortality during the follow-up period. Thus, a 
larger patient cohort is necessary to confirm our find-
ings. Secondly, this study was of a cross-sectional de-
sign and lacks repeated measurements of both OPG 
levels and PWV, limiting our ability to determine a 
causal relationship between OPG and arterial stiff-
ness. However, since we adjusted for multiple risk fac-
tors in our analysis, these limitations do not affect our 
conclusions.
In conclusion, our data suggest that the serum OPG, 
but not fetuin-A, level was associated with arterial 
stiffness in HD patients. Moreover, we determined 
that higher serum OPG levels were independent pre-
dictors of the onset of new CV events in HD patients. 
These findings suggest that serum OPG may be a clin-
ically useful marker for predicting vascular stiffness 
and that its measurement could facilitate evaluation of 
the risk of CV events in HD patients.
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